beclomethasone
Trade name: vanceril
Approved
May 12, 1976
Beclometasone or beclomethasone, also known as beclomethasone dipropionate, and sold under the brand name Qvar among others, is a steroid medication. It is available as an inhaler, cream, pills, and nasal spray. The inhaled form is used in the long-term management of asthma. The cream may be used for dermatitis and psoriasis. The pills have been used to treat ulcerative colitis. The nasal spray is used to treat allergic rhinitis and nasal polyps. — Wikipedia
Clinical trial activity
179 trials · 145 clinical orgs · 7 marketing orgs
Earliest trial started Jun 1, 1993 (NCT00000576)
Timeline
1970s
- May 12, 1976
Schering — Earliest FDA Approval
- May 12, 1976
Schering — NDA Secondary Org
- May 12, 1976
Schering — NDA Organization
- May 12, 1976
Schering-Plough — NDA Secondary Org
1980s
- Jun 24, 1980
GlaxoSmithKline — NDA Secondary Org
2010s
- Aug 3, 2017
Norton Waterford — NDA Secondary Org
2020s
- Dec 16, 2025
Amneal Pharmaceuticals — Marketing Organization
- May 14, 2026
Chiesi — NDA Secondary Org
Indications
Approved for
Studied for
- Airway Management · Phase 4
- Anesthesia, Endotracheal · Phase 4
- Breast Neoplasms · Phase 1/Phase 2
- Bronchial Diseases · Phase 2
- Bronchial Spasm · Phase 4
- Bronchiectasis · Phase 3
- Bronchiolitis · Early Phase 1
- Bronchopulmonary Dysplasia · Phase 3
- Burkitt Lymphoma · Phase 2
- COVID-19 · Phase 2
- Croup · Phase 3
- Doping in Sports · Phase 4
- Dyspnea · Phase 4
- Emphysema · Phase 4
- Enteritis · Phase 1/Phase 2
- Eosinophilic Esophagitis · Phase 1
- Folliculitis · Phase 2/Phase 3
- Gestational Trophoblastic Disease · Phase 1/Phase 2
- Graft vs Host Disease · Phase 3
- Healthy Volunteers · Phase 1
- HIV · Phase 1
- HIV Infections · Phase 2
- Hodgkin Disease · Phase 2
- Hyaline Membrane Disease · Phase 3
- Idiopathic Pulmonary Fibrosis · Phase 2
- Intestinal Neoplasms · Phase 3
- Kidney Neoplasms · Phase 1/Phase 2
- Leukemia · Phase 1/Phase 2
- Leukemia, Eosinophilic, Acute · Phase 2
- Leukemia, Hairy Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Lymphoid · Phase 4
- Leukemia-Lymphoma, Adult T-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 2
- Leukemia, Neutrophilic, Chronic · Phase 2
- Lung Diseases · Phase 3
- Lung Transplantation · Phase 1/Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Lymphomatoid Granulomatosis · Phase 2
- Macular Edema · Phase 1/Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Nasal Polyps · Phase 2
- Neuroblastoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pharmacokinetics · Phase 1
- Physical Functional Performance · Phase 4
- Plasmacytoma · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Primary Myelofibrosis · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Respiratory Sounds · Phase 4
- Respiratory Tract Diseases · Phase 3
- Respiratory Tract Infections · Phase 4
- Retinal Vein Occlusion · Phase 1/Phase 2
- Rhinitis, Allergic · Phase 4
- Rhinitis, Allergic, Perennial · Phase 3
- Sezary Syndrome · Phase 2
- Signs and Symptoms, Respiratory · Phase 4
- Sinusitis · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Status Asthmaticus · Phase 4
- Testicular Neoplasms · Phase 1/Phase 2
- Thrombocythemia, Essential · Phase 2
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Combination products
trimbow
with glycopyrronium, formoterol
Approval history
- approvedPriority reviewMay 12, 1976
Chemistry & pharmacology
SMILES
CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C)C(=O)CO- Mol. weight
- 464.979 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaBeclometasone ↗
- NCATS5BGA9FD55H ↗
- ChEMBLCHEMBL1200500 ↗
- NCATSKGZ1SLC28Z ↗
Also known as
- (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
- (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
- 9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
- 9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
- 9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
- 9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
- aerobec 100
- aerobec 50
- aerobec fte 250
- agn208397
- albuterol - beclomethasone
- albuterol, beclomethasone drug combinations
- asmabec clickhaler
- asmabec clickhaler
- asmabec spacehaler
- beclamethasone dipropionate
- beclazone 100
- beclazone 100 e-breathe
- beclazone 200
- beclazone 250
- beclazone 250
- beclazone 250 e-breathe
- beclazone 50
- beclazone 50 e-breathe
- becloaqua 50
- becloforte
- becloforte
- becloforte e-breathe
- becloforte integra
- becloforte-vm
- beclometasone
- beclometasone
- beclometasone
- beclometasone 17,21-dipropionate
- beclometasone 17,21-dipropionate
- beclometasone dipropionate
- beclometasone dipropionate
- beclometasone dipropionate
- beclometasone dipropionate
- beclometasone dipropionate
- beclometasone dipropionate
- beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium
- beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide
- beclomet diprop
- beclomethasone
- beclomethasone
- beclomethasone
- beclomethasone
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate
- beclomethasone dipropionate monohydrate
- beclomethasone dipropionate monohydrate
- beclomethasone dipropionate monohydrate
- beclomethasone dipropionate monohydrate
- beclomet hayfever
- beclomist
- beclotaide
- beclovent
- beclovent
- becodisks
- becodisks
- beconase
- beconase
- becotide
- becotide
- becotide 100
- becotide 100 e-breathe
- becotide 200
- becotide 50
- becotide 50 e-breathe
- chf1535
- chf 1535
- chf5993
- chf 5993
- chlorofluorocarbon beclomethasone
- chlorofluorocarbon beclomethasone dipropionate
- clenil
- clenil
- clenil modulite
- clipper
- clipper
- filair 100
- filair 50
- filair fte
- fostair
- fostair nexthaler
- nasobec aq
- nasobec hayfever
- propaderm
- propaderm
- propaderm-a
- propaderm-c
- propaderm fte
- pulvinal beclomet
- qnasl
- qnasl
- qvar
- qvar
- qvar 100
- qvar 100 e-breathe
- qvar 40
- qvar 40
- qvar 50
- qvar 50 e-breathe
- qvar 80
- qvar 80
- rino clenil
- rino clenil
- sch-18020w
- sch-18020w
- sgx201
- vancenase
- vancenase
- vancenase aq
- vancenase aq
- vancenase pockethaler
- vanceril
- vanceril
- vanceril
- vanceril double strength
- vanceril double strength
- ventide
- ventide
- ventide
- ventolin flogo
- vivabec
- zonivent aquanasal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07301736 | Phase 2 | Dec 15, 2025 | Chiesi |
| NCT07267273 | N/A | Nov 10, 2025 | Cairo University |
| NCT06482294 | Phase 2 | Jun 18, 2024 | University of Ferrara |
| NCT06264674 | Phase 3 | Nov 27, 2023 | Chiesi |
| NCT05970731 | Phase 2 | Sep 5, 2023 | Duke University |
| NCT05888350 | N/A | Jul 30, 2023 | Capital Medical University, China Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou Medical University, Henan Medical University, Henan Provincal People's Hospital, Huazhong University of Science and Technology, Huizhou Third People's Hospital, Inner Mongolia International Mongolian Hospital, Jiao Tong University, Jilin University, Peking University, Shanxi Medical University, Shenzhen University, Southern Medical University, The First People's Hospital of Yunan Province, Zunyi Medical College |
| NCT05898984 | Phase 1 | Apr 24, 2023 | Chiesi, SGS Life Sciences |
| NCT05830071 | Phase 1 | Mar 29, 2023 | Chiesi, Parexel |
| NCT06869382 | Phase 4 | Jan 1, 2023 | Tzu Chi University |
| NCT06139029 | Early Phase 1 (Phase 1) | Nov 15, 2022 | Mardan Medical Complex |
| NCT05352191 | Phase 4 | Sep 1, 2022 | Government of Norway, Western Norway University of Applied Sciences |
| NCT05292586 | Phase 3 | Aug 31, 2022 | Chiesi |
| NCT05018598 | Phase 4 | Jan 31, 2022 | Chiesi |
| NCT06657066 | Phase 2/Phase 3 (Phase 3) | Dec 6, 2021 | King Edward Medical University |
| NCT04873063 | Phase 1 | Oct 31, 2021 | SOFAR S.p.A. |
| NCT05097014 | Phase 4 | Oct 27, 2021 | Chiesi, LungenClinic Grosshansdorf |
| NCT04671355 | Phase 4 | Oct 4, 2021 | Chiesi, University of Central Lancashire, University of Dundee |
| NCT04937543 | Phase 2 | Jun 28, 2021 | Chiesi, Sao Paulo State University |
| NCT04876677 | Phase 3 | May 25, 2021 | Chiesi |
| NCT04817800 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2021 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. |
Organizations
Research & Development (145)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 75 | 67 | 4 | 2002 |
| Teva | For profit | 23 | 19 | 5 | 2004 |
| University of Manchester | Academic/Hospital | 8 | 0 | 2 | 2009 |
| University of Dundee | Academic/Hospital | 6 | 5 | 2 | 2009 |
| Merck | For profit | 5 | 5 | 3 | 1993 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 5 | 2 | 1 | 1993 |
| University of Colorado, Denver | Academic/Hospital | 5 | 1 | 3 | 1999 |
| Washington University in St. Louis | Academic/Hospital | 5 | 2 | 3 | 2004 |
| Pennsylvania State University | Academic/Hospital | 4 | 4 | 2 | 2004 |
| University of Ferrara | Academic/Hospital | 4 | 3 | 3 | 2009 |
| Cornell University | Academic/Hospital | 3 | 3 | 2 | 2002 |
| Duke University | Academic/Hospital | 3 | 1 | 2 | 2008 |
| Harvard University | Academic/Hospital | 3 | 0 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2000 |
| Soligenix | For profit | 3 | 3 | 2 | 2009 |
| University of Antwerp | Academic/Hospital | 3 | 3 | 3 | 2008 |
| University of Washington | Academic/Hospital | 3 | 2 | 2 | 2000 |
| University of Wisconsin | Academic/Hospital | 3 | 0 | 1 | 2004 |
| Adamis Pharmaceuticals Corporation | For profit | 2 | 2 | 1 | 2019 |
| Allegheny Health Network | Academic/Hospital | 2 | 2 | 1 | 2012 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Dec 16, 2025 |
| Chiesi | For profit | NDA2 | May 14, 2026 |
| GlaxoSmithKline | For profit | NDA2 | Jun 24, 1980 |
| Norton Waterford | For profit | NDA2 | Aug 3, 2017 |
| Schering | For profit | NDA2 | May 12, 1976 |
| Schering | For profit | NDA | May 12, 1976 |
| Schering-Plough | For profit | NDA2 | May 12, 1976 |
| Teva | For profit | NDA2 | Sep 15, 2000 |